Literature DB >> 24610636

Charge profiling and stability testing of biosimilar by capillary isoelectric focusing.

Junzi Cao1, Wen Sun, Feifei Gong, Wanhui Liu.   

Abstract

CIEF was developed for the rapid analysis of charge heterogeneity of trastuzumab biosimilar using commercially available fluorocarbon-coated capillary. The CIEF master mix was composed of 0.30% w/v methyl cellulose, 2.3 M urea, 56.8 mM l-arginine, 1.52 mM iminodiacetic acid, 4.5% v/v carrier ampholytes (broad-range pI 3-10 and narrow-range pI 8-10.5 with ratio of 3:1), and 0.45% v/v 10.0, 9.5, 7.0, 5.5, 4.1 pI markers. To get a robust method to analyze charge heterogeneity, some separation parameters, including focusing time and separation temperature, were investigated and optimized. The optimized method gave good precision in estimated pI values of charge variants with RSDs of not more than 0.16% intraday analysis (n = 6) and < 0.18% interday analysis (n = 9). In addition, the applications of this method including purity, stability, lot consistency, peptide N-glycosidase F digest, and C-terminal lysine variants characterization were also investigated.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CIEF; Charge heterogenity; Monoclonal antibody; Trastuzumab biosimilar

Mesh:

Substances:

Year:  2014        PMID: 24610636     DOI: 10.1002/elps.201300471

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  3 in total

1.  Rapid quantitative analysis of monoclonal antibody heavy and light chain charge heterogeneity.

Authors:  Ram P Vanam; Michael A Schneider; Michael S Marlow
Journal:  MAbs       Date:  2015-08-25       Impact factor: 5.857

2.  Intact and middle-down CIEF of commercial therapeutic monoclonal antibody products under non-denaturing conditions.

Authors:  Johannes Schmailzl; Marcel W Vorage; Hanno Stutz
Journal:  Electrophoresis       Date:  2020-04-27       Impact factor: 3.535

3.  Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab.

Authors:  Jennifer Liu; Tamer Eris; Cynthia Li; Shawn Cao; Scott Kuhns
Journal:  BioDrugs       Date:  2016-08       Impact factor: 5.807

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.